Timber Pharmaceuticals, Inc. TMBR
Set alert
0.34 +0.34 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 1.18M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.06
- Beta
- -0.65
- Short ratio
- 0.21
- Inst. own
- 7.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 4, 2023
- 50-d avg
- 1.88
- 200-d avg
- 2.00
- 1y target
- 0.00
2Y chart
Events in this range
- Aug 11, 2022Earnings: —; estimate -2; surprise —%
- Nov 9, 2022Split: 1 for 50
- Nov 14, 2022Earnings: —; estimate -2; surprise —%
- Mar 30, 2023Earnings: —; estimate -1.5; surprise —%
- May 15, 2023Earnings: —; estimate -1.17; surprise —%
- Aug 21, 2023Earnings: —; estimate -0.79; surprise —%
- Dec 4, 2023Earnings: —; estimate 0; surprise —%
Signals (69)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Dec 14, 2023 | 2 years ago |
| SMA: Bearish | Nov 16, 2023 | 2 years ago |
| RSI: Oversold | Nov 16, 2023 | 2 years ago |
| RSI: Oversold | Nov 1, 2023 | 3 years ago |
| SMA: Bearish | Oct 26, 2023 | 3 years ago |
| SMA: Bullish | Oct 24, 2023 | 3 years ago |
| SMA: Bearish | Oct 23, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 11, 2023 | 3 years ago |
| RSI: Overbought | Aug 31, 2023 | 3 years ago |
| SMA: Bullish | Aug 21, 2023 | 3 years ago |
| SMA: Bullish | Aug 21, 2023 | 3 years ago |
| RSI: Overbought | Aug 21, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 14, 2023 | 3 years ago |
| RSI: Oversold | Aug 2, 2023 | 3 years ago |
| SMA: Bearish | Jul 20, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jul 6, 2023 | 3 years ago |
| SMA: Bullish | Jul 5, 2023 | 3 years ago |
| SMA: Bearish | Jul 3, 2023 | 3 years ago |
| SMA: Bullish | Jun 30, 2023 | 3 years ago |
| RSI: Overbought | Jun 30, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| MACD: Buy Signal | May 30, 2023 | 3 years ago |
| MACD: Sell Signal | May 26, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 17, 2023 | 3 years ago |
| RSI: Oversold | Apr 12, 2023 | 3 years ago |
| SMA: Bearish | Mar 21, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 15, 2023 | 3 years ago |
| RSI: Overbought | Feb 27, 2023 | 3 years ago |
| SMA: Bullish | Feb 24, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 24, 2023 | 3 years ago |
| SMA: Bearish | Feb 23, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 7, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 1, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 30, 2023 | 3 years ago |
| SMA: Bullish | Jan 3, 2023 | 3 years ago |
| RSI: Oversold | Dec 6, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 23, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 9, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 8, 2022 | 3 years ago |
| RSI: Oversold | Oct 28, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 27, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 19, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 5, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 18, 2022 | 4 years ago |
| RSI: Oversold | Aug 17, 2022 | 4 years ago |
| RSI: Oversold | Jul 26, 2022 | 4 years ago |
| SMA: Bearish | Jul 18, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 6, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 28, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 23, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 22, 2022 | 4 years ago |
| SMA: Bullish | Jun 17, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 16, 2022 | 4 years ago |
| SMA: Bearish | Jun 13, 2022 | 4 years ago |
| SMA: Bullish | Jun 3, 2022 | 4 years ago |
| MACD: Buy Signal | May 19, 2022 | 4 years ago |
| MACD: Sell Signal | May 18, 2022 | 4 years ago |
| MACD: Buy Signal | May 13, 2022 | 4 years ago |
| MACD: Sell Signal | May 12, 2022 | 4 years ago |
| MACD: Buy Signal | May 6, 2022 | 4 years ago |
| RSI: Oversold | May 2, 2022 | 4 years ago |
| SMA: Bearish | Apr 8, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 7, 2022 | 4 years ago |
| SMA: Bullish | Mar 21, 2022 | 4 years ago |
| SMA: Bearish | Mar 18, 2022 | 4 years ago |
| SMA: Bullish | Mar 16, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 8, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 23, 2022 | 4 years ago |
Key statistics
- Market cap
- 1.18M
- Enterprise value
- -916.94K
- Trailing P/E
- 0.00
- Forward P/E
- -0.06
- PEG ratio
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -1.97
- Beta
- -0.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -6.18M
- Total cash
- 2.52M
- Total debt
- 545.13K
- Return on equity
- 0.00%
- Shares outstanding
- 3.43M
- Short % of float
- 0.23%
- 50-day average
- 1.88
- 200-day average
- 2.00
Analyst view
Consensus: hold
Hold
Price target (mean) 0.00
Next earnings
Dec 4, 2023
Expected Dec 4, 2023. Consensus EPS estimate -1.26.
Financials — quick view
TMBR Revenue — quarterly 0
TMBR Net income — quarterly -4.06M
TMBR EPS — quarterly -1.32
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 4, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 21, 2023 | Jun 1, 2023 | -0.79 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -1.17 | — | — | — |
| Mar 30, 2023 | Dec 1, 2022 | -1.50 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -2.00 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -2.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 9, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. On November 17, 2023, Timber Pharmaceuticals, Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- timberpharma.com
News
- Nasdaq Tumbles 2%; Timber Pharmaceuticals Shares Spike Higher
- Stocks That Hit 52-Week Lows On Monday
- Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
- Stocks That Hit 52-Week Lows On Wednesday
- Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
- Stocks That Hit 52-Week Lows On Friday
- Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
- Nasdaq Jumps 270 Points; Silver Surges Over 8%
- Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
- S&P 500 Surges 2%; Crude Oil Rises Sharply
Your note
Sign in to keep a note on TMBR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COHEN DAVID E | Director | Stock Award(Grant) | Apr 13, 2023 | 6,100 |
| GAAL LUBOR | Director | Stock Award(Grant) | Apr 13, 2023 | 6,100 |
| KOCONIS JOHN | Chief Executive Officer | Stock Award(Grant) | Aug 17, 2023 | 70,785 |
| LUCCHESE JOSEPH | Chief Financial Officer | Stock Award(Grant) | Aug 17, 2023 | 35,193 |
| MENDELSOHN ALAN | Officer | Stock Award(Grant) | Aug 17, 2023 | 35,432 |
| PIROZZI GIANLUCA | Director | Stock Award(Grant) | Apr 13, 2023 | 6,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.13% | 38,687 | 94.01K | Jun 29, 2023 |
| Citadel Advisors Llc | 0.97% | 33,185 | 80.64K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.58% | 19,799 | 48.11K | Jun 29, 2023 |
| State Street Corporation | 0.42% | 14,442 | 35.09K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.09% | 2,924 | 7.11K | Jun 29, 2023 |
| UBS Group AG | 0.02% | 800 | 1.94K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.13% | 38,687 | 94.01K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.41% | 13,966 | 20.25K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.15% | 5,291 | 7.67K | May 30, 2023 |